Elevated Risk of Intrahepatic Cholestasis of Pregnancy in SLE Patients Treated with Azathioprine
Overview
This study investigates the risk of intrahepatic cholestasis of pregnancy (ICP) in pregnant women with systemic lupus erythematosus (SLE) who are treated with azathioprine (AZA). Findings indicate a significant association between AZA exposure and increased ICP risk.
Background
Intrahepatic cholestasis of pregnancy (ICP) is a common liver disorder during pregnancy, linked to adverse maternal and fetal outcomes. The use of azathioprine, an immunosuppressive medication for SLE, raises concerns about its potential contribution to ICP.
Data Highlights
No numerical data or trial data were provided in the source material.
Key Findings
ICP has an incidence of 0.5% to 1.5% in the United States and is associated with elevated bile acids and adverse outcomes.
Thiopurines, including azathioprine, have been linked to an increased risk of ICP in pregnant women.
A Swedish nationwide registry study indicated a three-fold increased risk of ICP with AZA in SLE patients.
Prospective cohort studies are needed to evaluate the risk of ICP in AZA-exposed SLE pregnancies.
Clinical Implications
Healthcare providers should be aware of the potential increased risk of ICP in pregnant patients with SLE treated with azathioprine.
Conclusion
The study highlights the association between azathioprine exposure and ICP in SLE pregnancies.
by Reem Farhat, Maria del Carmen Zamora-Medina, Sang-Cheol Bae, Megan R. W. Barber, Ann E. Clarke, Paul R. Fortin, Zahi Touma, Carl A. Laskin, Isabelle Malhamé, Giada Sebastiani, Christine Peschken, Manuel F. Ugarte-Gil, Alexandra Legge, Sasha Bernatsky, Évelyne Vinet
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from September 1 - 15.
